Stockreport

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

iTeos Therapeutics, Inc.  (ITOS) 
PDF - EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from [Read more]